CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2025 Top Employers Survey for the eleventh consecutive year. Moderna was recognized for its commitment to continuous innovation and a culture that reflects the values of its employees. "We are honored to be recognized by... Read More

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025. The event will include presentations from management discussing Moderna's development and commercial strategy and key business considerations. A live webcast of the presentation will be available under "Events and Presentations" in... Read More

Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate any impact to its 2025 financial guidance or its expectation of achieving breakeven in 2028 CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal... Read More

CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. The details of the presentations are as follows: Late-Breaking Oral Presentation #229: mRNA-1010, an mRNA-Based Influenza Vaccine, is Safe and Efficacious in Adults Aged ≥50 Years : The presented... Read More

CAMBRIDGE, MA, MA / ACCESS Newswire / October 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to report its third quarter 2025 financial results, and provide a corporate update. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website. Webcast:... Read More

mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA, MA / ACCESS Newswire / October 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical, safety and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in checkpoint inhibitor-resistant/refractory(CPI-R/R) melanoma patients will be presented at the 2025 European Society for... Read More

The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population The facility marks a cornerstone of Moderna's ten-year strategic partnership with the UK Government, designed to strengthen health resilience and drive economic growth CAMBRIDGE, MA / ACCESS Newswire / September 24, 2025 / Moderna, Inc.... Read More

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains CAMBRIDGE, MA / ACCESS Newswire / September 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary... Read More

CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured in Canada are being shipped to provinces and territories. This milestone advances Canada's domestic vaccine production capacity and strengthens national health security. "The delivery of the first made-in-Canada mRNA vaccines to provinces and territories across the country marks a major milestone in... Read More

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data supporting recent FDA approval of 2025-2026 formula of Spikevax CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc . (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026... Read More

CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc . (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM), which will be held September 2-6, 2025 in Kyoto, Japan, at the Kyoto International Conference Center. This includes three oral presentations and two poster... Read More

CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2025-2026 formulas for Spikevax® and mNEXSPIKE®, targeting the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. The updated formula for Spikevax is now approved for individuals 6 months through 64... Read More

All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna announced today that Health Canada has authorized its updated COVID-19 mRNA vaccine, Spikevax®, targeting the SARS-CoV-2 LP.8.1 variant, for individuals aged six months and older. Moderna is on track to deliver the updated vaccine in time for the 2025-2026 vaccination... Read More

CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc . (NASDAQ:MRNA) today announced its participation in the following upcoming investor conferences: Morgan Stanley's 23 rd Annual Global Healthcare Conference, on Monday, September 8 th at 10:00am ET Bernstein Insights: Healthcare Leaders and Disruptors, on Thursday, September 25 th at 10:30am ET A live webcast of each of these presentations will be available... Read More

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end, primarily driven by timing of deliveries for contracted revenue into the first quarter of 2026 Improves 2025 expected GAAP operating expenses by approximately $400 million to a range of $5.9 to $6.1 billion... Read More

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent. This decision affirms the High Court's initial ruling from July 2024 that the EP'949 patent is valid and infringed by Pfizer/BioNTech's COVID-19 vaccine, Comirnaty®, which was subsequently appealed by Pfizer/BioNTech. With this ruling, the UK becomes... Read More

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. This marketing authorization follows the Positive... Read More

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) Congress, which will be held October 17-21, 2025 in Berlin, Germany. This includes a mini oral presentation on mRNA-4359, Moderna's investigational mRNA-based therapy designed to... Read More

Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision CAMBRIDGE, MA / ACCESS Newswire / July 25, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for an updated... Read More

mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older CAMBRIDGE, MA / ACCESS Newswire / June 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive results from a Phase 3 efficacy study (P304) evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010,... Read More

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59... Read More

CAMBRIDGE, MA / ACCESS Newswire / June 11, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor event: Barclays Speaking the Science Call Series, on Monday, June 16 th at 10:00am ET A live webcast of this presentation will be available under "Events and Presentations" in the Investors section of the Moderna website. investors.modernatx.com . A replay of this webcast will be... Read More

mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mNEXSPIKE ® (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for... Read More

Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire / May 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study ( NCT05972174 ) evaluating the safety and immunogenicity of its investigational... Read More

CAMBRIDGE, MA / ACCESS Newswire / May 27, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Jefferies Global Health Care Conference, on Thursday, June 5 th at 10:30am ET Goldman Sachs 46 th Annual Global Healthcare Conference, on Wednesday, June 11 th at 8:40am ET A live webcast of each of these presentations will be available under "Events and... Read More

CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the SARS-CoV-2 variant LP.8.1. The submission is based on guidance from the U.S. FDA, which advised that COVID-19 vaccines should be updated to a monovalent JN.1 lineage, with a preference for... Read More

CAMBRIDGE, MA / ACCESS Newswire / May 21, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced that in consultation with the U.S. Food and Drug Administration (FDA), the Company has voluntarily withdrawn the pending Biologics License Application (BLA) for mRNA-1083, its flu/COVID combination vaccine candidate for adults aged 50 years and older. The Company plans to resubmit the BLA later this year, after vaccine efficacy data... Read More

CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Bernstein's 41 st Annual Strategic Decisions Conference (SDC), on Thursday, May 29 th at 10:00am ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website. investors.modernatx.com... Read More

Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52) Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of approximately $6 billion Announces reduction of $1.4 to $1.7 billion in estimated GAAP operating costs by 2027 Advancing up to 10 products toward approval, including multiple oncology candidates CAMBRIDGE, MA / ACCESS Newswire... Read More

CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report its first quarter 2025 financial results, and provide a corporate update. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website. Webcast:... Read More

CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox, at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Vienna, Austria, from April 11-15, 2025.... Read More

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older. 1 mRESVIA's approval marks a significant milestone as it is the first mRNA... Read More

mRESVIA ® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus... Read More

CAMBRIDGE, MA / ACCESS Newswire / February 25, 2025 / Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 45 th Annual Health Care Conference, on Wednesday, March 5 th at 9:10am ET Barclays 27 th Annual Global Healthcare Conference, on Tuesday, March 11 th at 1:30pm ET A live webcast of each of these presentations will be available under "Events and... Read More

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing Reports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28) Expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billion Submitted three... Read More

CAMBRIDGE, MA / ACCESS Newswire / January 29, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 14, 2025 to report its fourth quarter and full year 2024 financial results, and provide a corporate update. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.... Read More

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats CAMBRIDGE, MA / ACCESS Newswire / January 24, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the resulting... Read More

CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the... Read More

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) Updates 2025 expected revenue range to $1.5 to 2.5 billion Expects to reduce 2025 cash cost expenses by $1.0 billion with a plan for additional 2026 cost reductions of $0.5 billion Updates 2025 expected ending cash balance to approximately $6.0 billion Anticipates milestones across 10... Read More

CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: 7 th Annual Evercore ISI HealthCONx Conference, on Wednesday, December 4 th at 1:20pm ET Piper Sandler 36 th Annual Healthcare Conference, on Thursday, December 5 th at 10:30am ET A live webcast of each of these presentations will be available under "Events and... Read More

CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace 's 2025 Best Places to Work report based on the Company's reputation and commitment to innovation. "We are honored to be recognized by BioSpace as the most desirable large employer in the life sciences industry for the fourth year in a row," said Stéphane Bancel, Chief Executive... Read More

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA following approvals in the U.S., Europe, and Qatar CAMBRIDGE, MA / ACCESSWIRE / November 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced Health Canada has approved mRESVIA™ (Respiratory Syncytial Virus mRNA vaccine) for... Read More

Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03 Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billion Initiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenza Announces expansion of its Executive Committee CAMBRIDGE, MA / ACCESSWIRE /... Read More

CAMBRIDGE, MA / ACCESSWIRE / October 31, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences: Guggenheim's Inaugural Healthcare Innovation Conference, on Tuesday, November 12 th at 10:00am ET UBS Global Healthcare Conference, on Wednesday, November 13 th at 3:30pm PT Jefferies London Healthcare Conference, on Thursday, November 21 st at 2:00pm GT A live webcast... Read More

CAMBRIDGE, MA / ACCESSWIRE / October 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2024 Top Employers Survey for the tenth consecutive year. Moderna was recognized for its commitment to continuous innovation, treating employees with respect, and social responsibility. "We are honored to be recognized among the... Read More

CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website. Webcast:... Read More

Hussain brings more than 35 years of commercial leadership and operating experience in healthcare, most recently serving as CEO of Vifor Pharma As former Global President of GSK, Pharmaceuticals and Vaccines, Hussain brings significant global vaccine commercialization experience in emerging and mature markets, along with significant Board of Directors expertise CAMBRIDGE, MA / ACCESSWIRE / October 2, 2024 / Moderna, Inc.... Read More

CAMBRIDGE, MA and TAIPEI, TAIWAN / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Cenra Healthcare , the sales and marketing arm of Cenra Inc., today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Taiwan, including Moderna's COVID-19 vaccine, Spikevax®. Under the agreement, Moderna will manufacture and... Read More

CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized clinical trial evaluating the efficacy, safety, and immunogenicity of an investigational norovirus vaccine, mRNA-1403. Global recruitment for the Nova 301 trial has also begun. "Norovirus is a significant public health concern... Read More

SPIKEVAX ® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians this fall and winter season. Moderna will promptly begin delivery of updated COVID-19 vaccines to the Public Health Agency of Canada, so there is robust supply available in time for provincial and territorial vaccination campaigns. CAMBRIDGE, MA / ACCESSWIRE / September 17, 2024 / Moderna... Read More

Focuses on ten product approvals through 2027 Expects to submit next-generation COVID vaccine for approval in 2024 Expects to submit flu/COVID combination vaccine for approval in 2024 Announces positive Phase 3 results for its RSV vaccine for high-risk adults aged 18 to 59; expects to submit sBLA for U.S. approval in 2024 Announces positive Phase 3 results for its standalone flu vaccine for adults aged 65 and older relative... Read More

Milestone marks a significant step toward producing mRNA vaccines in Canada by 2025 CAMBRIDGE, MA / ACCESSWIRE / September 9, 2024 / Moderna, Inc. (Nasdaq:MRNA) today announced that its manufacturing facility in Laval, Quebec, has been granted a Drug Establishment License (DEL) from Health Canada. This certification affirms the facility's compliance with rigorous safety and quality standards, authorizing it to produce drug... Read More

Moderna's updated COVID-19 mRNA vaccine will be available for the 2024-2025 vaccination season, pending a European Commission authorization decision CAMBRIDGE, MA / ACCESSWIRE / September 5, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for an updated... Read More

Approval follows recommendation from global public health bodies to develop JN.1 COVID-19 vaccines At present, the JN.1 group of subvariants remain dominant in the UK The updated vaccine will be available for eligible groups as part of the NHS autumn vaccination program, and will also be available to purchase privately in the UK for the first time CAMBRIDGE, MA / ACCESSWIRE / September 3, 2024 / Moderna, Inc. (Nasdaq:MRNA)... Read More

CAMBRIDGE, MA / ACCESSWIRE / September 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Taiwan Food & Drug Administration (FDA) has approved an updated formulation of the COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1., for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. In April 2024 , the World Health Organization (WHO) Technical... Read More

CAMBRIDGE, MA / ACCESSWIRE / August 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for mRESVIA ® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The marketing authorization follows the Positive Opinion from the European Medicines... Read More

CAMBRIDGE, MA / ACCESSWIRE / August 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change application for an updated formulation of its COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1. "We appreciate the Ministry of Health, Labour and Welfare approval decision for our updated COVID-19 mRNA... Read More

Spikevax 2024-2025 formula expected to be available in pharmacies and care settings across the U.S. in the days immediately following approval CAMBRIDGE, MA / ACCESSWIRE / AUGUST 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Spikevax® (2024-2025 formula) for individuals 12 years and above. Emergency Use... Read More

CAMBRIDGE, MA / ACCESSWIRE / August 22, 2024 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - R&D Day and Business Updates at 9:00 a.m. ET on Thursday, September 12, 2024. The event will include presentations from management discussing Moderna's development and commercial strategy and key business considerations. A live webcast of the presentation will be available under "Events and... Read More

Companies share joint commitment to leveraging technology for STEM education Accessible education on cutting-edge science and technology represents critical step toward closing workforce readiness gap CAMBRIDGE, MA and MOUNTAIN VIEW, CA / ACCESSWIRE / August 14, 2024 / Moderna, Inc. (NASDAQ:MRNA) and Coursera (NYSE:COUR) today announced a partnership to launch mRNAs as Medicines , a three-module course designed by experts at... Read More

Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33) Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billion Received U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July; received EMA positive opinion in June Announced positive Phase 3 data for combination vaccine against influenza and COVID-19 Announced positive... Read More

Co-Founder and Co-Chairman of The Carlyle Group brings multi-industry investor experience and global policy expertise, replacing retiring director Stephen Berenson Co-founder and director Robert Langer also to retire from the Moderna Board; recruitment efforts ongoing for his replacement CAMBRIDGE, MA / ACCESSWIRE / July 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that David M. Rubenstein, Co-Founder and... Read More

CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website. Webcast:... Read More

CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including Moderna's COVID-19 vaccine, Spikevax®. Under the agreement, Moderna will handle the manufacturing, sales, medical education and... Read More

CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR)... Read More

CAMBRIDGE, MA / ACCESSWIRE / June 28, 2024 / Moderna, Inc. (Nasdaq:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorization in the European Union for mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower... Read More

mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and older Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older CAMBRIDGE, MA / ACCESSWIRE / June 13, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1283, an... Read More

mRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older, including an enhanced influenza vaccine in adults 65 years and older CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza... Read More

Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending regulatory approval CAMBRIDGE, MA / ACCESSWIRE / June 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2024-2025 formula, targeting the SARS-CoV-2 variant JN.1. "For four years, Moderna... Read More

Center for Biologics Evaluation and Research has chosen mRNA-3705 as one of four investigational medicines for accelerated development to address unmet medical needs for rare diseases CAMBRIDGE, MA / ACCESSWIRE / June 6, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START)... Read More

At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patients The 2.5-year recurrence-free survival rate of mRNA-4157 (V940) in combination with KEYTRUDA was 74.8% as compared to 55.6% for KEYTRUDA alone, with the benefit observed... Read More

mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes CAMBRIDGE, MA / ACCESSWIRE / May 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by... Read More

Moderna to host an investor event via webcast on Monday, June 3 at 6:15 PM CDT CAMBRIDGE, MA / ACCESSWIRE / May 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 - June 4 in Chicago, IL.... Read More

CAMBRIDGE, MA / ACCESSWIRE / May 13, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Bernstein's 40th Annual Strategic Decisions Conference (SDC), on Friday, May 31 st at 10:00am ET Jefferies Healthcare Conference, on Thursday, June 6 th at 10:00am ET Goldman Sachs 45th Annual Global Healthcare Conference, on Monday, June 10 th at 1:20pm ET A live webcast... Read More

U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024 Agency has indicated it expects to complete the review by end of May CAMBRIDGE, MA / ACCESSWIRE / May 10, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that due to administrative constraints, the... Read More

Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07) Prepares for launches of RSV vaccine and Spikevax ® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billion Initiated three new clinical studies evaluating Moderna's investigational individualized neoantigen therapy in combination with Merck's Keytruda ® for treatment of patients with... Read More

CAMBRIDGE, MA / ACCESSWIRE / April 25, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present data from its respiratory portfolio, including vaccines and vaccine candidates against COVID-19 (mRNA-1273, mRNA-1283), influenza (mRNA-1010, mRNA-1011/1012), and respiratory syncytial virus (RSV) (mRNA-1345), along with data related to its latent virus portfolio regarding cytomegalovirus (CMV), at the... Read More

Generative AI will help advance Moderna's broad and diverse portfolio to maximize the Company's impact on patients Moderna embeds OpenAI's generative AI tools throughout its organization and sees early success with broad adoption of ChatGPT Enterprise CAMBRIDGE, MA AND SAN FRANCISCO, CA / ACCESSWIRE / April 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) and OpenAI today announced their ongoing collaboration to co-innovate with a... Read More

CAMBRIDGE, MA / ACCESSWIRE / April 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a contract with the Ministry of Health in Brazil (Ministério da Saúde) to supply its mRNA COVID-19 vaccine as an integral part of Brazil's 2024 national vaccination campaign against COVID-19. This contract follows the Brazilian Health Regulatory Agency's (ANVISA) approval of Moderna's COVID-19 vaccine in March 2024, which encodes the... Read More

CAMBRIDGE, MA / ACCESSWIRE / April 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024 to report its first quarter 2024 financial results, and provide a corporate update. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website. Webcast:... Read More

CAMBRIDGE, MA / ACCESSWIRE / April 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that interim data for a first-in-human, phase 1/2, open-label, dose optimization study and extension study, evaluating the safety and efficacy of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA), has been published in Nature . "We are excited to share the first published clinical data utilizing an mRNA therapy for... Read More

Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpoints Expects two more Phase 3 readouts in 2024, including combination vaccine against flu and COVID-19, and vaccine against CMV Announces positive clinical trial data from three new vaccines against viruses that cause significant burden (Epstein-Barr virus, Varicella-Zoster virus, norovirus) and advances... Read More

mRNA-1283 induced a more robust immune response compared to Spikevax ® COVID-19 vaccine, mRNA-1273.222 Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against influenza and COVID-19, mRNA-1083 CAMBRIDGE, MA / ACCESSWIRE / March 26, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation... Read More

CAMBRIDGE, MA / ACCESSWIRE / February 29, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host its fifth annual Investor Event focused on vaccines and business updates on Wednesday, March 27, 2024. The presentation will begin at 9:00 a.m. ET. Moderna's Investor Event will include presentations from management on Moderna's pipeline of mRNA vaccines. A live webcast will be available under "Events and... Read More

CAMBRIDGE, MA / ACCESSWIRE / February 28, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 44 th Annual Healthcare Conference, on Wednesday March 6 th at 1:30 pm ET. Barclays 26 th Annual Global Healthcare Conference, on Tuesday March 12 th at 2:35 pm ET. A live webcast of each of these presentations will be available under "Events and... Read More

Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55 Reports full-year revenues of $6.8 billion, GAAP net loss of $(4.7) billion and GAAP diluted EPS of $(12.33); loss primarily driven by mostly non-cash charges of $3.7 billion related to resizing and a tax valuation allowance Reaffirms 2024 expected product sales of approximately $4 billion Expects regulatory approvals... Read More

CAMBRIDGE, MA / ACCESSWIRE / February 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that Stéphane Bancel, Chief Executive Officer, has been elected to the National Academy of Engineering (NAE), broadly known as one of the highest acknowledgments of achievement in the field, in recognition of distinguished contributions to engineering and the "development and manufacturing of pharmaceutical products, including the... Read More

CAMBRIDGE, MA / ACCESSWIRE / February 1, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024 to report its fourth quarter and full year 2023 financial results, and provide a corporate update. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website. Webcast:... Read More

CAMBRIDGE, MA / ACCESSWIRE / January 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it has been recognized on Fortune 's World's Most Admired Companies list as part of its "All-Star" top-50 companies. This annual list is considered one of the leading measures of corporate reputation among global organizations. "We are honored to be recognized among the most admired companies in the world. This marks our first year on... Read More

Company announces product sales for 2023 of approximately $6.7 billion (unaudited); U.S. COVID-19 market share season to date increased to 48% in 2023, up from 37% in 2022 Company reiterates 2024 expected product sales of approximately $4 billion, planned return to sales growth in 2025 and expectation to break even in 2026 through product launches and disciplined investment Company highlights nine late-stage programs with... Read More

CAMBRIDGE, MA / ACCESSWIRE / December 20, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced that Jamey Mock, Chief Financial Officer, will present at the 42nd annual J.P. Morgan Healthcare Conference on Monday, January 8th at 6:45 p.m. ET / 3:45 p.m. PT. A live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com . A... Read More

Moderna has submitted marketing authorizations globally for mRNA-1345 and continues to prepare for an expected 2024 marketing launch CAMBRIDGE, MA / ACCESSWIRE / December 15, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced the publication of positive Phase 3 clinical study results evaluating mRNA-1345, its vaccine candidate for respiratory syncytial virus (RSV), in The New England Journal of Medicine . The peer-reviewed... Read More

At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.288-0.906]; one-sided nominal p=0.0095) and the risk of distant metastasis or death by 62% (HR=0.384 [95% CI, 0.172-0.858]; one-sided nominal p= 0.0077) compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following... Read More

CAMBRIDGE, MA / ACCESSWIRE / December 12, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced changes to its operating model to bring focus to its short- and long-term business goals. The Company is focused on driving continued sales of its COVID-19 vaccine and launching its RSV vaccine in 2024, while also preparing to launch multiple products per year from 2025 forward. The Company has decided to increase executive focus on... Read More

The Company's ESG strategy demonstrates its efforts to advance global health and environmental sustainability, as well as its commitments to employees and communities CAMBRIDGE, MA / ACCESSWIRE / December 7, 2023 / Moderna, Inc. (NASDAQ:MRNA) today will provide an update on its Environmental, Social and Governance (ESG) strategy at its second ESG Investor Event. Building off its inaugural ESG Day in November 2022, the... Read More

CAMBRIDGE, MA / ACCESSWIRE / November 14, 2023 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host its second virtual ESG investor event at 8:00 a.m. ET on Thursday, December 7, 2023. Moderna's ESG Investor Event will include presentations from management on Moderna's ESG strategy. A live webcast of the event will be available under "Events and Presentations" in the Investors section of the Moderna website.... Read More

CAMBRIDGE, MA / ACCESSWIRE / November 8, 2023 / Moderna, Inc . (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: 2023 UBS Global Biopharma Conference on November 9 th at 8:00 a.m. ET. 2023 Jefferies London Healthcare Conference on November 16 th at 8:30 a.m. GMT. 35 th Annual Piper Sandler Healthcare Conference on November 30 th at 12:30 p.m. ET. A live webcast of each... Read More

The Company demonstrates how its integrated Artificial Intelligence ecosystem accelerates innovation at scale and creates value across the enterprise Moderna to present case studies on how the organization is building a real-time AI Company CAMBRIDGE, MA / ACCESSWIRE / November 8, 2023 / Moderna, Inc. (NASDAQ:MRNA) today will unveil its comprehensive AI and digital strategy at its second Digital Investor Event. Building off... Read More

CAMBRIDGE, MA / ACCESSWIRE / November 7, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2024 Best Places to Work report for the third consecutive year. "We are proud to be named the best place to work on BioSpace's 2024 ranking for the third year in a row," said Stéphane Bancel, Chief Executive Officer of Moderna. "This recognition is a testament to the unique... Read More

Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billion Spikevax U.S. market share to date increased to 45% from 36% in 2022 Company anticipates 2024 revenue of approximately $4 billion and return to growth in 2025 Company has significantly improved future cost of sales by resizing its manufacturing capacity, contributing to a third quarter net loss of $3.6 billion, primarily driven... Read More

New partnership will harness Moderna's mRNA rapid-response platform, clinically validated during the COVID-19 pandemic, to accelerate epidemic and pandemic vaccine development First project will enable rapid pre-clinical testing of antigen designs for high-risk viral families, to advance global outbreak readiness CAMBRIDGE, MA / ACCESSWIRE / October 30, 2023 / The Coalition for Epidemic Preparedness Innovations (CEPI) and... Read More

CAMBRIDGE, MA / ACCESSWIRE / October 26, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as one of the top employers in the global biopharmaceutical industry in Science and Science Careers' 2023 Top Employers Survey for the ninth consecutive year. Moderna was recognized for its commitment to continuous innovation, treating employees with respect, and social responsibility. "We are again honored to be... Read More

mRNA-1083 is Moderna's first respiratory combination vaccine candidate to enter a Phase 3 trial Phase 3 initiation follows data from a Phase 1/2 trial where mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines Company has multiple programs in Phase 3 development across several areas, including respiratory... Read More

Partnership enables Moderna to leverage Caris' vast library of de-identified, multi-modal data and analytics capabilities to accelerate precision medicine and the delivery of novel medicines to patients IRVING, Texas , Oct. 24, 2023 /PRNewswire/ -- Caris Life Sciences ® (Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to... Read More

CAMBRIDGE, MA / ACCESSWIRE / October 19, 2023 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a virtual Digital and AI Investor Event at 8:00 a.m. ET on Wednesday, November 8, 2023. The event will include presentations from management discussing Moderna's digital strategy and the role of AI in accelerating its innovation, scale and value creation. The company will discuss a range of AI applications across... Read More

CAMBRIDGE, MA / ACCESSWIRE / October 12, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 2, 2023 to report its third quarter 2023 financial results, and provide a corporate update. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website. Webcast:... Read More

mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines Company to begin Phase 3 trial of mRNA-1083 in adults 50 years and above CAMBRIDGE, MA / ACCESSWIRE / October 4, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced positive interim results from the Phase 1/2 trial of mRNA-1083, an investigational combination... Read More

CAMBRIDGE, MA / ACCESSWIRE / September 29, 2023 / Moderna, Inc. (NASDAQ:MRNA) has become aware that TRC Capital Investment Corporation (TRC Capital) has amended its unsolicited "mini-tender" offer to purchase up to 1,000,000 shares of Moderna's common stock, at an offer price that is now $99.00 per share, down from $107.56 per share under the original offer. TRC Capital's amended offer price of $99.00 per share is lower than... Read More

The positive opinion follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccines for autumn/winter 2023 vaccination campaigns Clinical trial data from research assay confirmed Moderna's updated COVID-19 vaccine showed an 8.7 to 11-fold increase in neutralizing antibodies against circulating variants, including BA.2.86, EG.5, and FL.1.5.1 variants CAMBRIDGE, MA /... Read More

Company's flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial; separate Phase 1/2 data demonstrated higher HAI titers than Fluzone HD Vaccine pipeline advancing rapidly with Company announcing the completion of RSV BLA filing (mRNA-1345), completion of adult enrollment in the Phase 3 trial of mRNA-1647, a first-in-class vaccine against CMV, and the Phase 3 trial of mRNA-1283, a next-generation COVID-19 vaccine... Read More

Clinical data show robust immune responses across multiple circulating variants, including EG.5, FL.1.5.1, and BA.2.86 Updated vaccine to be available in pharmacies and care settings across the U.S. in the coming days CAMBRIDGE, MA / ACCESSWIRE / September 11, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application(sBLA) for... Read More

CAMBRIDGE, MA / ACCESSWIRE / September 8, 2023 / Moderna, Inc. (Nasdaq:MRNA) has been notified that TRC Capital Investment Corporation (TRC Capital) has made an unsolicited "mini-tender" offer to purchase up to 1,000,000 shares of Moderna's common stock, at an offer price of $107.56 per share. TRC Capital's offer price of $107.56 per share is approximately 4.44% lower than the closing price of Moderna common stock on the... Read More

CAMBRIDGE, MA / ACCESSWIRE / September 6, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in a fireside chat at Morgan Stanley's 21st Annual Global Healthcare Conference on Tuesday, September 12th at 12:15 p.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com . A replay of the webcast will... Read More

CDC notes that the BA.2.86 (Pirola) variant may be more likely to break through existing immunity from previous vaccination or infection, highlighting the need for vaccination with an updated COVID-19 vaccine for the fall 2023 season Clinical trial data from research assay confirmed Moderna's updated COVID-19 vaccine showed an 8.7 to 11-fold increase in neutralizing antibodies against circulating variants, including BA.2.86,... Read More

CAMBRIDGE, MA / ACCESSWIRE / August 30, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - R&D Day and Business Updates at 1:00 p.m. ET on Wednesday, September 13, 2023. The event will include presentations from management discussing Moderna's development and commercial strategy and key business considerations. A live webcast of the presentation will be available under "Events and... Read More

Updated COVID-19 vaccine effectively targets EG.5, a dominant variant of concern, as well as the rapidly spreading FL 1.5.1 variant Updated vaccine expected to be available, pending approval, in coming weeks for fall vaccination season CAMBRIDGE, MA / ACCESSWIRE / August 17, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced that preliminary clinical trial data confirm its updated COVID-19 vaccine for the fall 2023... Read More

Study participants include children up to and including 36 months who attend group child care and early childhood education settings located in Worcester and Cambridge WORCESTER, Mass. , Aug. 14, 2023 /PRNewswire/ -- UMass Chan Medical School today announced it will begin enrolling participants at group child care and early childhood education settings in Worcester and Cambridge to examine the impact of cytomegalovirus (CMV)... Read More

Second quarter 2023 revenues of $0.3 billion; net loss of $1.4 billion and loss per share of $3.62 Company expecting 2023 COVID-19 vaccine sales of $6 billion to $8 billion, dependent on U.S. vaccination rates Company submitted its investigational RSV vaccine to several regulators globally ahead of potential 2024 launch With its partner Merck, the Company began Phase 3 trial of mRNA-4157, its individualized neoantigen... Read More

CAMBRIDGE, MA / ACCESSWIRE / July 13, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 3, 2023 to report its second quarter 2023 financial results, and provide a corporate update. A live webcast of the call will be available under "Events and... Read More

Moderna has submitted marketing authorization applications for the investigational RSV vaccine, mRNA-1345, with the European Medicines Agency, Swissmedic, and the Therapeutic Goods Administration in Australia The Company has also initiated a rolling submission of a Biologics License Application to the U.S. Food and Drug Administration for mRNA-1345 mRNA-1345 met primary efficacy endpoints, demonstrating vaccine efficacy of... Read More

The filing follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccines Pending approval, Moderna's updated COVID-19 vaccine will be available for fall vaccination with ample and timely supply Preliminary clinical data show that the company's XBB1.5 monovalent vaccine induces an immune response against viruses of the XBB lineage CAMBRIDGE, MA / ACCESSWIRE / July... Read More

Health Canada submission follows international recommendations to develop monovalent XBB.1.5 COVID-19 vaccines Moderna is prepared to deliver updated COVID-19 vaccines in time for the fall 2023 vaccination season TORONTO , June 29, 2023 /CNW/ - Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has initiated the filing of a rolling New Drug... Read More

Preliminary clinical data demonstrated a robust immune response by the company's XBB.1.5 monovalent vaccine against XBB descendent lineage viruses Pending authorization, Moderna's updated COVID-19 vaccine would be available in time for fall vaccination Supply readiness follows months of manufacturing to ensure timely and ample supply CAMBRIDGE, MA / ACCESSWIRE / June 22, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology... Read More

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA alone The DMFS results, a key secondary endpoint of the Phase 2b KEYNOTE-942 study, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Companies plan to initiate a Phase 3 study in the adjuvant setting in... Read More

CAMBRIDGE, MA / ACCESSWIRE / June 1, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences: 2023 Jefferies Healthcare Conference on Thursday, June 8 th at 10:30 a.m. ET 44 th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 14 th at 4:40 p.m. PST A live webcast... Read More

ASCO presentations on Saturday, June 3 at 4:30pm CDT and Monday, June 5 at 3:00pm CDT Moderna to host investor event via webcast on Monday, June 5 at 6pm CDT CAMBRIDGE, MA / ACCESSWIRE / May 30, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy,... Read More

First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement To date, mRNA-3927 has been generally well-tolerated at the doses administered, with encouraging early signs of dose-dependent pharmacology and potential clinical benefits No occurrence of dose-limiting toxicities or study discontinuations due to drug-related treatment-emergent adverse events (TEAEs) More than 280 doses of... Read More

Vaccines manufactured at Moderna's state-of-the-art Canadian mRNA facility to be prepared and packaged at Novocol's Ontario -based facility Fill-finish agreement will secure domestic end-to-end vaccine production and ensures rapid response capabilities for future pandemic readiness for Canadians TORONTO , May 4, 2023 /CNW/ - Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics... Read More

First quarter 2023 revenues of $1.9 billion; GAAP net income of $79 million and GAAP diluted EPS of $0.19 Company in negotiations for new orders for fall of 2023 in U.S., Japan, and EU, in addition to reiterating 2023 minimum sales expectations of approximately $5.0 billion from previously announced COVID-19 vaccine Advanced Purchase Agreements Company preparing for potential 2024 commercial launch of its investigational RSV... Read More

After completing enrollment in 5 dose cohorts, and with no dose-limiting safety signals observed to date by the independent DSMB, the Phase 1/2 trial of mRNA-3927 advances to the dose-expansion phase to determine a recommended dose CAMBRIDGE, MA / ACCESSWIRE / May 3, 2023 / Moderna,Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that an abstract reporting... Read More

The Enterprise Solutions Hub in the Philippines will support the Asia Pacific region and complements Moderna's Enterprise Solutions Hubs in Warsaw, Poland, and Atlanta, U.S. The Philippines was selected due to its mature global business service environment, favorable infrastructure and business climate, and accessibility of broad and diverse talent The Company also plans to establish a commercial presence in the Philippines... Read More

CAMBRIDGE, MA / ACCESSWIRE / April 20, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 4, 2023 to report its first quarter 2023 financial results, and provide a corporate update. A live webcast of the call will be available under "Events and... Read More

Moderna invests in developing quantum computing skills and exploring the use of quantum computing in developing future mRNA medicines Agreement with IBM includes investments in generative AI to improve product design CAMBRIDGE, MA and ARMONK, NY / ACCESSWIRE / April 20, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and IBM (NYSE:IBM) today announced an... Read More

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection Results from the Phase 2b KEYNOTE-942 trial selected for AACR press program Companies will initiate a Phase 3 study in patients with adjuvant melanoma in 2023, and rapidly expand to additional tumor types, including... Read More

Next-generation, refrigerator-stable COVID-19 vaccine candidate, mRNA-1283, has dosed first participant in its Phase 3 trial Company expects to file for approval of its investigational RSV vaccine candidate, mRNA-1345, this quarter Company's first influenza candidate, mRNA-1010, did not accrue sufficient cases at the interim efficacy analysis to declare early success in the Phase 3 Northern Hemisphere efficacy trial and the... Read More

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / April 6, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced... Read More

Facility to enable access to manufactured mRNA vaccines for Kenya and the African continent, providing health security and building upon Moderna's global public health commitments The facility will be capable of producing up to 500 million doses each year CAMBRIDGE, MA & NAIROBI, KENYA / ACCESSWIRE / March 30, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and... Read More

CAMBRIDGE, MA / ACCESSWIRE / March 24, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will present its Vaccines Day for analysts and investors at 8:00 a.m. ET on Tuesday, April 11, 2023. Moderna's Vaccines Day will include presentations from management and key opinion leaders (KOLs) on Moderna's mRNA vaccines and key... Read More

CAMBRIDGE, MA / ACCESSWIRE / March 14, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157/V940 an investigational mRNA personalized cancer vaccine, have been accepted for presentation at the 2023 American Association of Cancer Research (AACR) Annual Meeting being held April 14-19 in Orlando, FL. mRNA-4157/V940... Read More

Expansion includes new West Coast offices in South San Francisco, California and Seattle, Washington New offices complement existing locations in Cambridge, MA; Norwood, MA; Atlanta, GA; Bethesda, MD; and Princeton, NJ Moderna currently has offices in 17 locations worldwide Company plans to hire approximately 2,000 new employees in 2023 CAMBRIDGE, MA / ACCESSWIRE / March 10, 2023 / Moderna, Inc. , (NASDAQ:MRNA) a... Read More

CAMBRIDGE, MA / ACCESSWIRE / February 28, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at Cowen's 43rd Annual Health Care Conference on Monday, March 6 th at 9:10 a.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna... Read More

Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61 Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS of $20.12 Company reiterating approximately $5 billion in COVID-19 sales contracted for delivery in 2023 and expecting additional sales from key markets Company will file for regulatory approval for mRNA-1345, Moderna's... Read More

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / February 22, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in... Read More

Collaboration to combine Moderna's mRNA platform with Life Edit's proprietary gene editing technologies, including base editing capabilities Multi-target collaboration to advance potentially life-transformative or curative therapies for some of the most challenging genetic diseases Life Edit to receive upfront cash payment, research, and preclinical funding, and is eligible to receive milestone payments with tiered royalties... Read More

The recommendation is based on clinical data for Moderna's bivalent Omicron-targeting COVID-19 vaccine, mRNA.1273.214 Moderna's bivalent Omicron-targeting COVID-19 vaccines (mRNA.1273.214 (BA.1) & mRNA.1273.222 (BA.4/5)) are currently authorized for use in individuals 18 years of age and older in Canada Both bivalents have been shown to trigger a superior antibody response compared to a booster dose of mRNA-1273, the... Read More

mRNA-1010 demonstrated superiority on seroconversion rates for A/H3N2 and A/H1N1, superiority on geometric mean titer ratios for A/H3N2, and non-inferiority on geometric mean titer ratios for A/H1N1 Non-inferiority was not met for seroconversion rates and geometric mean titer ratios for the influenza B/Victoria- and B/Yamagata-lineage strains mRNA-1010 showed an acceptable safety and tolerability profile Separate parallel... Read More

CAMBRIDGE, MA / ACCESSWIRE / February 2, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 23, 2023 to report its fourth quarter and full year 2022 financial results, and provide a corporate update. A live webcast of the call will be available under... Read More

Designation based on positive topline data from the ConquerRSV Phase 3 pivotal efficacy trial, which demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults CAMBRIDGE, MA / ACCESSWIRE / January 30, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced mRNA-1345, an... Read More

mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults mRNA-1345 was generally well-tolerated, with no safety concerns identified by the DSMB Based on these results, Moderna intends to submit mRNA-1345 for regulatory approval CAMBRIDGE, MA, ACCESSWIRE / January 17, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering... Read More

COVID-19 vaccine sales for 2022 approximately $18.4 billion (unaudited) Reiterating 2023 expected minimum COVID-19 vaccine sales of approximately $5.0 billion; continue to expect additional contracts for 2023 Company continues to scale with 48 programs in development, including 36 in ongoing clinical studies, and is increasing R&D investment to an expected $4.5 billion for 2023 Pivotal Phase 3 RSV study of mRNA-1345 in older... Read More

Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million upfront payment with the potential for additional research, milestone, and royalty payments CAMBRIDGE, MA and SOUTH SAN FRANCISCO, CA / ACCESSWIRE / January 5, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering... Read More

OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines Acquisition will bolster Moderna's suite of platform technologies CAMBRIDGE, MA and TOKYO, JAPAN / ACCESSWIRE / January 4, 2023 / Moderna, Inc . (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and OriCiro Genomics K.K., a pioneer in cell-free DNA... Read More

CAMBRIDGE, MA / ACCESSWIRE / January 3, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at the 41st annual J.P. Morgan Healthcare Conference on Monday, January 9th at 5:15 p.m. ET. A live webcast of the presentation will be... Read More

Facility to enable access to domestically manufactured mRNA respiratory vaccines, pending regulatory assessment and licensure The ten-year strategic partnership is expected to provide the UK public with response capabilities to ensure future preparedness in light of the COVID-19 pandemic Moderna is expanding its presence in the UK through investments in R&D activities and capabilities CAMBRIDGE, MA / ACCESSWIRE / December... Read More

Newly created role will have responsibility for commercial efforts in Europe, Middle East and Canada CAMBRIDGE, MA / ACCESSWIRE / December 20, 2022 / Moderna, Inc . (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of Chantal Friebertshäuser as Senior Vice President, Commercial, Europe, Middle East and Canada effective January 1, 2023. Ms.... Read More

The recommendation is based on clinical data for Moderna's bivalent Omicron-targeting COVID-19 vaccine, mRNA.1273.214 Moderna's bivalent Omicron-targeting COVID-19 vaccines (mRNA.1273.214 (BA.1) & mRNA.1273.222 (BA.4-5)) are approved for use in individuals 12 years of age and older in the European Union Both bivalents have been shown to trigger a superior antibody response compared to a booster dose of mRNA-1273, the... Read More

mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death compared to KEYTRUDA monotherapy in stage III/IV melanoma patients with high risk of recurrence following complete resection Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial Companies... Read More

mRNA-1273.222 Targets the BA.4/BA.5 Strains of Omicron Variant Authorization Is Based Upon Clinical and Pre-Clinical Data for Moderna's Bivalent Vaccines CAMBRIDGE, MA / ACCESSWIRE / December 8, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA)... Read More

Current Chief Digital Officer, Marcello Damiani, to retire in March CAMBRIDGE, MA / ACCESSWIRE / December 7, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of Brad Miller as Chief Information Officer effective January 3. Mr. Miller will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane... Read More

CAMBRIDGE, MA / ACCESSWIRE / November 29, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Thursday, Dec. 1 st at 9:00 a.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the... Read More

CAMBRIDGE, MA / ACCESSWIRE / November 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of David Jiménez as General Manager, United States, effective November 21, 2022. Mr. Jiménez will be responsible for commercial efforts in the United States, reporting to Arpa Garay, Moderna's Chief Commercial Officer. "David has... Read More

Moderna, Inc . (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change to a new drug application for its Omicron-targeting bivalent COVID-19 booster, mRNA-1273.222 (Spikevax Bivalent Original/Omicron BA.4-5) in adults 18 years and older. Spikevax Bivalent... Read More

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host its first virtual ESG Day for analysts and investors at 9:00 a.m. ET on Thursday, November 10. Moderna's ESG Day will include presentations from management on Moderna's mission and ESG journey, including a review of its first ESG report published in June. A live webcast will be... Read More

Moderna, Inc. , (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it was ranked one of the top employers in the global biopharmaceutical industry by Science and Science Careers' 2022 Top Employers Survey for the eighth consecutive year. Moderna was ranked no. 7 on the list this year and was recognized for its commitment to innovative leadership, respect for... Read More

Announcement follows CHMP's previous decision to issue a positive opinion recommending marketing authorization for Moderna's COVID-19 vaccine to include children 6 years of age and older Two-dose series takes one month to complete, with similar vaccine efficacy estimates against Omicron to those seen in adults Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines,... Read More

Data indicate durable immune response from bivalent booster after three months of follow-up mRNA-1273.214 also demonstrated potent response to Omicron BA.2.75 Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214. Ninety days after administration as a fourth booster dose in... Read More

Given the sufficient supply of COVID-19 vaccines globally, Moderna & Gavi have mutually agreed to cancel remaining pending orders under the current COVID-19 vaccine supply agreement for 2022 Gavi and Moderna have agreed to create a new framework that would enable Gavi to purchase up to 100 million doses of updated variant-specific COVID-19 vaccines in 2023, with all doses offered at Moderna's lowest-tiered price Moderna,... Read More

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 3, 2022 to report its third quarter 2022 financial results, and provide a corporate update. To access the live conference call via telephone, please register at the link below. Once registered, dial-in numbers... Read More

mRNA-1273.222 Targets the BA.4/BA.5 Strains of Omicron Variant Authorization Is Based Upon Clinical and Pre-Clinical Data for Moderna's Bivalent Vaccine Candidates Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its BA.4/BA.5... Read More

Companies on track to report data from the ongoing Phase 2 trial of mRNA-4157/V940 in combination with KEYTRUDA® as adjuvant therapy in high-risk melanoma in 4Q 2022 Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Merck has exercised its option to jointly develop and... Read More

Option exercised on undisclosed immune-oncology target following evaluation period by Moderna Autolus receives option exercise fee, with potential for development milestone payments plus royalties Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programed T cell therapies, today announces that Moderna (MRNA), a biotechnology company pioneering messenger RNA (mRNA)... Read More

Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion Jerh Collins Joins Moderna as Chief Technical Operations and Quality Officer to Succeed Juan Andres Moderna, Inc. , (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the Company has expanded the Executive Committee to prepare for multiple upcoming new product launches.... Read More

Filing follows approval of Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), a bivalent booster vaccine targeting the Omicron BA.1 subvariant, in September Moderna's Omicron-targeting bivalent boosters now authorized in the United States, Australia, Canada, Europe, Japan, South Korea, Switzerland, Singapore, Taiwan, and the UK Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA)... Read More

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change to a new drug application for its Omicron-targeting bivalent COVID-19 booster, mRNA-1273.214 (Spikevax Bivalent Original/Omicron BA.1). Spikevax Bivalent Original/Omicron contains... Read More

Interim data from Phase 1/2 propionic acidemia (PA) multi-dose Paramount trial shows mRNA-3927 was well-tolerated to date, with encouraging early signs of potential for clinical benefit Interim data from Phase 1/2 glycogen storage disease 1a (GSD1a) single-dose Ba1ance trial shows mRNA-3745 was well tolerated to date, with encouraging early signs of potential for clinical benefit Moderna announces a new development... Read More

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Stephen Hoge, M.D., President, will participate in a fireside chat at the Morgan Stanley 20 th Annual Global Healthcare Conference on Tuesday, September 13 th at 10:00 a.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the... Read More

mRNA-1273.214 is the first Omicron-targeting bivalent COVID-19 booster vaccine approved in Canada Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-1273 Approval follows agreement with the Government of Canada to supply 12 million doses of Omicron-targeting bivalent COVID-19 boosters Moderna, Inc . (NASDAQ:MRNA), a... Read More

Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-1273 Positive recommendation follows recent amendment to European Commission (EC) COVID-19 vaccine agreement to supply Omicron-targeting bivalent candidates In addition to the CHMP positive opinion, Moderna has received approvals for mRNA-1273.214 in Australia,... Read More

Moderna's Bivalent Booster Shots to be Available Nationwide In Coming Days mRNA-1273.222 Targets BA.4/.5 Strains of Omicron Variant Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its BA.4/.5 Omicron-targeting bivalent COVID-19 booster... Read More

Australia becomes among the first countries in the world to approve the use of a next-generation bivalent COVID-19 vaccine mRNA-1273.214, an Omicron-containing bivalent vaccine, has demonstrated significantly higher antibody titers against all tested variants, including Omicron BA.1 and BA.4/5 subvariants Moderna expects to supply mRNA-1273.214 to Australia in September Moderna, Inc. (NASDAQ:MRNA), a biotechnology company... Read More

Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it will host its in-person and virtual R&D Day at 9:00 a.m. ET on Thursday, September 8, 2022. Moderna's R&D Day will feature presentations from Stéphane Bancel, Chief Executive Officer, Stephen Hoge M.D., President, and Moderna clinical team leaders. A live webcast will be available under " Events... Read More

Switzerland becomes among the first countries in the world to approve the use of a next-generation bivalent COVID-19 booster vaccine Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-1273 Moderna is working with Swissmedic and the Government of Switzerland to make mRNA-1273.214 available in early September Moderna, Inc.... Read More

Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty® unlawfully infringes patents Moderna filed between 2010 and 2016 Moderna not seeking removal of Comirnaty® from market or injunction against future sales Company not pursuing monetary damages on sales to the 92 low- and middle-income countries in the GAVI COVAX Advance Market Commitment (AMC 92) Moderna,... Read More

mRNA-1273.222 Targets BA.4/BA.5 Strains of Omicron Variant Pending Authorization, Moderna Ready to Ship Bivalent Booster mRNA-1273.222 in September Clinical Data Available for Moderna's Bivalent COVID-19 Booster Vaccines Have Met All Primary Endpoints and Support Request for Emergency Use Authorization Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today... Read More

Government of Canada exercises option to purchase an additional 4.5 million doses of Moderna's Omicron-containing bivalent vaccine booster candidates Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Government of Canada has exercised its option to purchase an additional 4.5 million doses of an Omicron-containing bivalent vaccine booster... Read More

Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that James Mock has been appointed as Moderna's Chief Financial Officer, beginning September 6, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer Stéphane Bancel. Following the appointment of Mr. Mock, David Meline will retire as the Company's CFO effective... Read More

Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-1273 Moderna, Inc . (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted conditional authorization for the use of the... Read More

Contractually remaining doses of Moderna's COVID-19 vaccine (Spikevax, mRNA-1273) will be converted to Moderna's next generation Omicron-containing bivalent vaccines Moderna, Inc .(NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an amendment to its agreement with the European Commission (EC) to convert contractually agreed doses of Moderna's COVID-19 vaccine... Read More

Second quarter 2022 revenues of $4.7 billion; GAAP net income of $2.2 billion and GAAP diluted EPS of $5.24 Company reiterates advance purchase agreements for expected delivery in 2022 of approximately $21 billion Company announces new $3 billion share repurchase plan Company has four infectious disease vaccines in Phase 3 and expects data from proof-of-concept studies in rare diseases and immuno-oncology later this year... Read More

New U.S. government contract includes an award up to $1.74 billion for 66 million doses to be delivered in 2022; additional options, if exercised, may raise total to 300 million doses Moderna, Inc., (Nasdaq:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. government has secured 66 million doses of a Moderna COVID-19 vaccine booster candidate,... Read More

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a variation to the conditional marketing authorization (CMA) to include a booster dose of Spikevax, the Company's COVID-19 vaccine, at the 50 µg dose level for... Read More

Announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Argentina, Canada, Israel, the US, and Taiwan for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 months to five years Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has... Read More

Two-dose series takes one month to complete, with similar vaccine efficacy estimates against Omicron to those seen in adults Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Health Canada has approved the use of Moderna's mRNA COVID-19 vaccine, SPIKEVAX™, in a two-dose series of 25 µg per dose for active immunization to prevent COVID-19... Read More

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, August 3, 2022 to report its second quarter 2022 financial results, and provide a corporate update. To access the live conference call via telephone, please register at the link below. Once registered, dial-in numbers... Read More

Moderna advances global health commitment with mRNA vaccine candidate against the Nipah virus, a lethal pathogen with pandemic potential Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in a Phase 1 trial of its Nipah virus (NiV) vaccine candidate, mRNA-1215, that was developed in collaboration with the... Read More

mRNA-1273.214 has now demonstrated significantly higher antibody titers against all tested variants, including Omicron BA.1 and BA.4/5 subvariants, ancestral virus, Alpha, Beta, Delta, and Gamma Moderna has completed regulatory submissions for mRNA-1273.214 in EU, UK, and Australia, expects to complete most remaining filings this week Company simultaneously developing mRNA-1273.222, a bivalent candidate based on BA.4/5,... Read More

mRNA-1273.214 Exhibited a Greater Than 5-Fold Boost in Neutralizing Antibodies Against BA.4 and BA.5 Subvariants in Phase 2/3 Study Data Being Submitted to Regulators and for Peer Reviewed Publication Moderna, Inc. , (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its bivalent (Omicron) COVID booster candidate, mRNA-1273.214. One month... Read More

Manufacturing facility would provide access to domestically manufactured vaccines against respiratory viruses Moderna would expand its presence in the UK through investments in R&D activities and capabilities Collaboration would support the UK with direct access to rapid pandemic response capabilities Moderna, Inc . (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today... Read More

mRNA-1273 was authorized for children and adolescents aged 6 months through 17 years of age, administered as two doses given one month apart mRNA-1273 has been administered to millions of children and adolescents over the age of 6 worldwide, with safety and tolerability profiles consistent with other age groups Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines,... Read More

Data Show Significantly Higher Geometric Mean Titer Ratios, Meeting Prespecified Endpoints for Superiority Against Omicron Variant mRNA-1273.214 Exhibited an 8-Fold Boost in Neutralizing Geometric Mean Titers Against Omicron Among Baseline Seronegative Participants Safety and Tolerability Profile for mRNA-1273.214 is Consistent with Prior Booster Dose of mRNA-1273 Regulatory Submission Planned for Coming Weeks to Enable Use... Read More